Top Page
Australian Clinical Labs Ltd
(Sydney:ACL)
Australian Clinical Labs Ltd (ACL) vs. iShares MSCI Australia ETF (EWA)
Australian Clinical Labs Ltd Business Overview & Revenue Model
Australian Clinical Labs Ltd Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 741.27M | 741.27M | 689.73M | 692.10M | 989.30M | 641.31M |
| Gross Profit | 270.86M | 270.86M | 138.45M | 566.02M | 781.71M | 521.73M |
| EBITDA | 81.36M | 81.36M | 169.65M | 184.93M | 372.75M | 196.67M |
| Net Income | 32.43M | 32.43M | 23.93M | 35.90M | 178.24M | 60.37M |
Balance Sheet | ||||||
| Total Assets | 574.84M | 574.84M | 593.06M | 578.91M | 628.04M | 474.70M |
| Cash, Cash Equivalents and Short-Term Investments | 22.12M | 22.12M | 26.84M | 20.59M | 27.51M | 36.28M |
| Total Debt | 290.38M | 290.38M | 308.90M | 316.32M | 262.38M | 294.26M |
| Total Liabilities | 402.86M | 402.86M | 415.30M | 406.24M | 395.49M | 392.79M |
| Stockholders Equity | 171.35M | 171.35M | 177.53M | 172.42M | 232.44M | 81.90M |
Cash Flow | ||||||
| Free Cash Flow | 174.39M | 174.39M | 153.09M | 136.75M | 262.83M | 144.36M |
| Operating Cash Flow | 182.80M | 182.80M | 159.59M | 143.68M | 284.09M | 153.86M |
| Investing Cash Flow | -8.89M | -8.89M | -7.25M | -12.18M | -72.04M | -6.08M |
| Financing Cash Flow | -178.74M | -178.74M | -146.14M | -137.88M | -220.91M | -147.37M |
Australian Clinical Labs Ltd Technical Analysis
Australian Clinical Labs Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | AU$10.72B | 20.28 | 6.32% | 4.94% | 9.44% | -0.37% | |
63 Neutral | AU$495.35M | 14.75 | 18.59% | 4.94% | 6.73% | 37.16% | |
55 Neutral | AU$973.34M | 171.71 | 0.94% | 2.49% | 33.54% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | €584.54M | ― | -67.21% | ― | -23.02% | 33.11% |
Australian Clinical Labs Ltd Corporate Events
Australian Clinical Labs Ltd has announced the appointment of Stephen Roche as a director, effective from June 20, 2025. The announcement indicates that Roche currently holds no relevant interests in securities, suggesting a fresh start in his role, which may impact the company’s governance and strategic direction.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Limited has announced the appointment of Stephen Roche as a new independent non-executive director, who will transition to the role of Chair of the Board by August 2025. Roche brings extensive strategic and operational experience from various sectors, including healthcare, retail, and consumer goods, which is expected to strengthen ACL’s board and support its mission of improving patient outcomes through innovative pathology services.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Ltd has announced a change in the substantial holding of its shares, with Mitsubishi UFJ Financial Group, Inc. increasing its voting power from 5.01% to 6.08%. This change in shareholding could impact the company’s governance and strategic decisions, potentially influencing its market position and stakeholder interests.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Ltd has announced a change in the interests of a substantial holder, First Sentier Investors. The change affects the voting power and relevant interests in the company’s shares, with implications for the control and management of voting rights. This development could impact the company’s governance and influence its strategic decisions, as substantial holders play a significant role in shaping corporate policies.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Ltd announced the issuance of unquoted equity securities as part of an employee incentive scheme. This move involves the issuance of service rights and performance rights, which are not intended to be quoted on the ASX, indicating a strategic step to enhance employee engagement and retention.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Ltd announced the issuance and conversion of unquoted equity securities, specifically 59,046 ordinary fully paid shares, as part of its ongoing financial operations. This move reflects the company’s strategic efforts to manage its equity structure, potentially impacting its market positioning and offering implications for its stakeholders.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Ltd announced the issuance and conversion of unquoted equity securities, specifically 15,662 ordinary fully paid shares. This move is part of the company’s ongoing financial management and could impact its capital structure, potentially influencing its market positioning and stakeholder interests.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Ltd has announced a change in the interests of a substantial holder, Regal Funds Management Pty Ltd and its associates, in the company’s voting securities. This change reflects a shift in the voting power held by Regal Funds Management, which could impact the company’s governance and decision-making processes, potentially influencing its strategic direction and stakeholder interests.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Allan Gray Australia Pty Ltd, an investment manager, has increased its voting power in Australian Clinical Labs Ltd from 9.90% to 10.95%. This change in substantial holding reflects a strategic move by Allan Gray Australia, potentially impacting the company’s governance and influencing its strategic direction.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Allan Gray Australia Pty Ltd, an investment manager, has increased its voting power in Australian Clinical Labs Ltd from 8.79% to 9.90%. This change in substantial holding reflects a strategic move by Allan Gray Australia, potentially impacting the company’s shareholder dynamics and signaling confidence in the company’s market position.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Allan Gray Australia Pty Ltd, a substantial holder in Australian Clinical Labs Limited, has increased its voting power from 7.50% to 8.79% as of May 30, 2025. This change in interest may influence the company’s governance and strategic decisions, potentially impacting stakeholders and the company’s market positioning.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Limited has announced an update regarding its ongoing on-market buy-back program. The company reported that it bought back a total of 200,000 ordinary fully paid securities on the previous day, adding to a cumulative total of 5,842,629 securities repurchased. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Ltd has announced an update on its ongoing on-market buy-back program. As of May 29, 2025, the company has repurchased a total of 5,842,629 ordinary fully paid securities, including 150,000 bought back on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Ltd has announced an update regarding its ongoing share buy-back program. As of the latest notification, the company has repurchased a total of 5,692,629 ordinary fully paid securities, including 250,000 bought back on the previous day. This buy-back initiative is part of the company’s strategy to optimize its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Ltd announced the cessation of 750,000 ordinary fully paid securities due to an on-market buy-back, effective May 19, 2025. This move is part of the company’s capital management strategy, potentially impacting its share value and signaling a focus on optimizing shareholder returns.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Ltd has announced an update regarding its ongoing share buy-back program. The company has repurchased a total of 250,000 ordinary fully paid securities on the previous day, adding to the cumulative total of 5,192,629 securities bought back to date. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Ltd has announced an update regarding its ongoing share buy-back program. The company reported that it has bought back a total of 4,892,629 securities prior to the previous day and an additional 300,000 securities on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Ltd has announced an update on its ongoing share buy-back program, revealing that it bought back 300,000 ordinary fully paid securities on the previous day, adding to a total of 4,592,629 securities repurchased before that day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Allan Gray Australia Pty Ltd, acting as an investment manager for various funds, has increased its voting power in Australian Clinical Labs Ltd from 6.49% to 7.50% as of May 12, 2025. This change in substantial holding indicates a growing interest and influence in the company, potentially impacting its governance and strategic decisions.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Ltd has announced a change in the substantial holding of its shares, with Regal Funds Management Pty Limited and its associates now holding a significant interest. This change in voting power indicates a shift in shareholder dynamics, potentially impacting the company’s strategic decisions and market positioning.
Australian Clinical Labs Ltd announced an update on their ongoing share buy-back program, revealing that a total of 4,442,629 ordinary fully paid securities have been bought back to date. This buy-back initiative is part of the company’s strategy to enhance shareholder value and optimize its capital structure, potentially impacting its market positioning and stakeholder interests.
Australian Clinical Labs Ltd has announced an update regarding its ongoing on-market buy-back of ordinary fully paid securities. As of the latest notification, the company has bought back a total of 4,274,630 securities, with 150,000 purchased on the previous day. This buy-back initiative may impact the company’s stock value and shareholder equity, reflecting a strategic move to manage capital and potentially enhance shareholder returns.